Philip Ashton-Rickardt and the Art of Reinvention

Some careers follow a straight line. Philip Ashton-Rickardt did not. He started in academic science. Then he became a biotech founder. Later, he helped guide companies through acquisitions and major transitions. Along the way, he worked on some of the toughest challenges in medicine, including neurodegenerative diseases like ALS and multiple sclerosis.

Today, Ashton-Rickardt is Managing Director and Chief Scientific Officer at BE Therapeutics in Boston. But his story began far from the biotech world he now helps shape.

“I came from a working-class family,” he says. “I had to chart my own progress through college to an academic career.”

That experience stayed with him. It taught him independence early. It also shaped the way he approaches leadership, risk, and innovation.

How Philip Ashton-Rickardt built a career in immunology

Ashton-Rickardt studied biochemistry at King’s College London before earning a PhD in molecular biology at the University of Edinburgh. He later completed postdoctoral research at MIT.

At the time, immunology was moving quickly. Scientists were uncovering how the immune system could be used to fight disease in entirely new ways.

Ashton-Rickardt became part of that movement.

He went on to hold faculty positions at the University of Chicago and later Imperial College London. During those years, he published widely, led large research programs, and built a reputation in T-cell biology and immunology research.

But even as his academic career grew, he felt pulled toward something more practical.

“Trying to create something new and important,” he says, “was always the goal.”

Why he left academia for Biotech

By 2017, Ashton-Rickardt made a major decision. He left Imperial College London and returned to Boston to start Smith Therapeutics.

The move was risky. Leaving a senior academic position for a startup meant entering a completely different environment.

“There was serious career peril when I was at Imperial College,” he says. “That’s when I decided I wanted to leave academia and return to Boston to start a company.”

That company focused on CAR-engineered regulatory T cells, also known as CAR-Treg therapies. The idea was ambitious: use engineered immune cells to help treat neurodegenerative diseases.

At the time, many people still viewed these therapies as highly experimental.

But Ashton-Rickardt saw potential in applying immunology beyond cancer treatment.

He built the company from the ground up before selling its assets and intellectual property to AZTherapies.

The big ideas behind his work in cell therapy

One pattern appears throughout Ashton-Rickardt’s career: he gravitates toward difficult problems.

At AZTherapies, he led immunology programs tied to cell therapy platforms and biomarker discovery. Later, as Chief Scientific Officer at Sigilon Therapeutics, he oversaw the development of shielded cell therapies for rare and chronic diseases.

Sigilon was eventually acquired by Eli Lilly in 2023.

These leadership roles required more than scientific expertise. They demanded operational thinking, team building, and long-term planning.

“Resilience, flexibility, hard work, curiosity,” he says. “Those are the things that matter.”

Today, he continues that work through BE Therapeutics and Halyard Therapeutics, where he focuses on engineered therapies for brain disorders.

What makes a successful biotech leader?

Biotech can be unpredictable. Scientific setbacks are common. Timelines are long. Many ideas never reach patients.

That reality has shaped Ashton-Rickardt’s leadership style.

“I take one step at a time,” he says. “And I think back to when things were worse.”

He also believes strongly in authenticity.

“Being authentic and trying to be yourself,” he says, is critical in leadership roles.

Unlike some executives who focus heavily on hype, Ashton-Rickardt tends to speak in measured terms. He talks more about process than headlines. More about learning than certainty.

“I’m always learning,” he says.

That mindset helped him move through multiple industries and career phases without becoming stuck in one identity.

Lessons from building companies and scientific teams

Over the years, Philip Ashton-Rickardt has led teams ranging from academic labs to biotech organizations with dozens of scientists.

He says one of the most important parts of leadership is creating an environment where people can grow.

At Imperial College London, he managed a department of more than 90 scientists and oversaw millions of dollars in research funding. Later, in biotech, he helped recruit and lead multidisciplinary teams working across immunology, manufacturing, and clinical development.

But he also learned the importance of balance.

“Balance career with my family,” he says, is one of the lessons he values most.

Outside of work, he enjoys running, reading, writing, and following Liverpool Football Club.

How Philip Ashton-Rickardt turned big ideas into real impact

Philip Ashton-Rickardt’s career has never been about following the safest path.

Instead, it has been about taking scientific ideas that seemed difficult or uncertain and finding ways to move them forward.

Some of those ideas became companies. Others became therapies in development. All of them required persistence.

“I have my own standards,” he says.

That approach helped him move from academia into biotech leadership without losing the curiosity that started his career in the first place.

And in an industry built around solving hard problems, that may be what matters most.